Turn Therapeutics' GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine [Yahoo! Finance]
Turn Therapeutics Inc. (TTRX)
Company Research
Source: Yahoo! Finance
Turn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “ Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment ” by Patient Care Online Magazine “We are honored to have our GX-03 technology be recognized as a top innovation by this widely read online magazine and this surprise designation further validates our goal of bringing best-in-class eczema products to patients in need,” said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. “IL-36 is implicated in the inflammatory cascade behind atopic dermatitis, eczema and psoriasis, and our technology, with its novel mechanism of action, represents the first topi
Show less
Read more
Impact Snapshot
Event Time:
TTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TTRX alerts
High impacting Turn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TTRX
News
- Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. [Yahoo! Finance]Yahoo! Finance
- Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.GlobeNewswire
- Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online MagazineGlobeNewswire
TTRX
Sec Filings
- 11/25/25 - Form 4
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- TTRX's page on the SEC website